ClinicalTrials.gg
CompletedNCT00143195ANISSAUpdated Jan 28, 2021

Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina

A Phase 4 interventional study of Amlodipine and iso- 5 - mononitrate in Myocardial Ischemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 12 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of study is to compare the anti-ischemic efficacy and safety profiles of once daily amlodipine or isosorbide-5-mononitrate in the treatment of stable asymptomatic and symptomatic myocardial ischemia

02

Conditions studied

  • Myocardial Ischemia

Browse trials for

03

In context

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

This study's enrollment of 200 is above the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.

Browse Myocardial Ischemia studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients > =18 years of age with diagnosed clinically stable angina pectoris

Exclusion criteria

Exclusion Criteria:

  • Patients with congestive heart failure, cardiovascular disease, standing systolic blood pressure of less than 100mmHg, concomitant anti-anginal therapies similar to sublingual NTG
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the time to 1mm ST depression

Secondary outcomes

  1. The number of patients experiencing angina attacks The frequency of hospitalizations due to angina attacks Time to onset of 1mm ST segment depression Total external workload performed Safety

07

Study locations

12 sites
  • Pfizer Investigational Site
    Athens, Attika 11527, Greece
  • Pfizer Investigational Site
    Athens, 123 51, Greece
  • Pfizer Investigational Site
    Athens, Greece
  • Pfizer Investigational Site
    Holargos/Athens, 11525, Greece
  • Pfizer Investigational Site
    Loannina, 45500, Greece
  • Pfizer Investigational Site
    N. Ionia, 143 88, Greece
  • Pfizer Investigational Site
    Patra, 26335, Greece
  • Pfizer Investigational Site
    Rio, Patra, 26499, Greece
  • Pfizer Investigational Site
    Thessaloniki, 546 36, Greece
  • Pfizer Investigational Site
    Thessaloniki, 54639, Greece
  • Pfizer Investigational Site
    Voula/Athens, Greece
  • Pfizer Investigational Site
    Zakynthos, 29100, Greece
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Apr 2001
Completion
Jan 2005
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00143195
Responsible party
Sponsor
First posted
Sep 2, 2005
Start date
Apr 2001
Completion
Jan 2005
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion